MAPCA Coiling — Cost, Top Hospitals & Success Rates | MyMedicPlus

Major Aortopulmonary Collateral Arteries (MAPCAs) are anomalous vessels originating from the descending aorta (or its branches — subclavian, intercostal, coronary) that supply blood directly to the pulmonary parenchyma. They develop embryologically as persistence of ventral intersegmental arteries when true pulmonary arteries fail to form or are severely hypoplastic. MAPCAs are the defining feature of the most complex form of tetralogy of Fallot with pulmonary atresia (TOF-PA), also occurring in double outlet right ventricle with pulmonary atresia (DORV-PA), single ventricle physiology with pulmonary atresia, and isolated pulmonary atresia.

MAPCAs are anatomically highly variable in number (1–6 per patient), origin, size, and the specific pulmonary segments they supply. Individual segments may receive blood from a MAPCA alone (sole-supply) or from both a true central pulmonary artery and a MAPCA (dual-supply). This distinction is critically important for management: dual-supply MAPCAs create volume overload and competition, and can be safely coiled (embolised) to reduce pulmonary overcirculation; sole-supply MAPCAs are the only blood source to that segment and must be surgically incorporated (unifocalised) rather than embolised.

Comprehensive pre-procedural evaluation uses cardiac MRI (3D reconstruction, flow quantification) and cardiac catheterisation with selective MAPCA angiography to map each collateral vessel, its segmental supply territory, true pulmonary artery anatomy, pulmonary artery pressure, and the presence of stenoses within the MAPCA. Cardiac CT angiography (CTA) is increasingly used for initial anatomical mapping and pre-surgical 3D planning at experienced centres, often reducing the need for purely diagnostic catheterisation.

Primary Indications — Congenital Heart Disease with MAPCAs:

• Tetralogy of Fallot with Pulmonary Atresia (TOF-PA): The most common association. True pulmonary arteries are absent or severely hypoplastic; MAPCAs provide the sole source of pulmonary blood flow. Approximately 50% of patients with TOF-PA have MAPCAs as the primary pulmonary supply.
• Double Outlet Right Ventricle with Pulmonary Atresia (DORV-PA): Similar MAPCA anatomy to TOF-PA; management principles are identical.
• Single Ventricle with Pulmonary Atresia: Complex heterotaxy syndromes, isomerism (right or left atrial isomerism) with pulmonary atresia; MAPCAs add to the complexity of staged single-ventricle palliation (Glenn, Fontan procedures).
• Isolated Pulmonary Atresia with Intact Ventricular Septum (PA-IVS) with MAPCAs: Less commonly associated with MAPCAs but occurs in complex variants.

Physiological Consequences of Unmanaged MAPCAs:

• Volume overload: Dual-supply MAPCAs provide excess pulmonary blood flow, causing congestive cardiac failure, particularly in neonates and infants after corrective surgery when the right ventricle is loaded.
• Pulmonary hypertension: MAPCAs supplying unobstructed (non-stenotic) segments at systemic pressure cause hypertensive pulmonary vascular disease, potentially rendering affected segments inoperable.
• Haemoptysis: In older patients with chronic MAPCA-supplied segments developing high-pressure arterial walls — potentially life-threatening.
• Competitive flow after unifocalization: Residual dual-supply collaterals after surgical unifocalization compete with newly created central pulmonary arterial flow, creating steal and functional impairment of the right heart reconstruction.

• Dual-supply MAPCAs confirmed on catheterisation: The only MAPCAs that can be safely embolised are those supplying pulmonary segments that also receive flow from central true pulmonary arteries (dual supply). This must be confirmed by selective angiography and, when in doubt, by balloon occlusion testing.
• Pre-unifocalization preparation: Patients awaiting complete unifocalization surgery (Hanley procedure or staged unifocalization) may undergo catheter-based coiling of dual-supply MAPCAs to simplify subsequent surgical reconstruction and reduce post-operative volume load.
• Post-unifocalization residual collaterals: After surgical unifocalization and right ventricular outflow tract (RVOT) reconstruction, residual MAPCAs that were not incorporated may be identified. These compete with the newly established central pulmonary flow and are coiled at catheterisation within weeks to months of surgery.
• Staged palliation in complex single ventricle: Before bidirectional Glenn or Fontan completion, MAPCA coiling may be required to reduce volume overload on the systemic ventricle and optimise pulmonary vascular resistance.
• Contraindications to MAPCA coiling: Sole-supply MAPCAs (pulmonary segments with no alternative supply); MAPCAs that share origin with the spinal artery supply (artery of Adamkiewicz) without confirmatory balloon occlusion testing and alternative spinal supply; haemodynamic instability; active coagulopathy.

1. Pre-Procedural MAPCA Mapping
Before any coiling, complete anatomical mapping is mandatory. The sequence is:

• Cardiac MRI / CT angiography: 3D reconstruction of the aorta and its branches, true pulmonary arteries, and large MAPCAs. Quantification of pulmonary blood flow (Qp:Qs ratio) and segmental supply.
• Selective catheter angiography: Each MAPCA is selectively catheterised and injected to define origin, course, stenoses, and the specific bronchopulmonary segments supplied. True pulmonary artery angiography simultaneously demonstrates segments with dual supply.
• Spinal artery mapping: MAPCAs originating from the descending thoracic aorta or intercostal/subcostal vessels must be carefully evaluated for spinal cord supply. The artery of Adamkiewicz (arteria radicularis magna) — the dominant anterior spinal artery typically originating from a left intercostal or upper lumbar vessel (T9–L2) — must be identified on angiography before coiling any thoracic MAPCA. Inadvertent embolisation of the Adamkiewicz artery causes anterior spinal cord infarction and paraplegia.

2. Balloon Occlusion Testing
When the supply classification of a MAPCA is uncertain (possible sole-supply vs dual-supply), a compliant occlusion balloon is inflated within the vessel under fluoroscopy, and the patient is observed for desaturation (monitored by pulse oximetry and, in conscious patients, neurological symptoms). Significant oxygen desaturation during occlusion indicates the segment has no alternative supply — the vessel must not be coiled and should be incorporated at surgery. Stable saturation during occlusion confirms dual supply, permitting safe embolisation. This test must be performed with readily available resuscitation equipment and under experienced supervision.

3. Coil Embolisation
Detachable platinum coils are the most widely used embolic device for MAPCA occlusion. Coils are delivered via microcatheter into the target vessel; the thrombogenic matrix induces thrombus formation and permanent occlusion. Advantages: precise deployment, ability to reposition detachable coils before release, available in multiple sizes and shapes (helical, tornado, complex-shape coils). Multiple coils are often required to achieve complete occlusion of larger MAPCAs. Key limitation: recanalization — established thrombus within a coil mass may recanalise over time (weeks to months), requiring repeat embolisation. Recanalization rates for MAPCAs are higher than for many other vascular structures because MAPCAs carry high-pressure aortic flow.

4. Amplatzer Vascular Plug II (AVP II)
The Amplatzer Vascular Plug II (St Jude Medical / Abbott) is a self-expanding nitinol mesh plug available in sizes 3–22 mm, specifically designed for occlusion of arteriovenous fistulae and large vessels. In MAPCA coiling, AVP II offers several advantages over coils:

• Single-device occlusion of large-diameter MAPCAs (up to 22 mm) — avoids the need for multiple coils and reduces procedure time.
• Low-profile delivery system; sheaths required are smaller than surgical ligation.
• Lower recanalization rate compared to coils alone in high-flow, high-pressure vessels.
• Retrievable before complete deployment if malpositioned.

In practice, many operators use a combination strategy: AVP II for the main vessel body to reduce flow, followed by coil packing to complete occlusion, or coil embolisation of side branches feeding the MAPCA before AVP II deployment in the main trunk.

5. Staged Unifocalization vs Catheter-Based Coiling — The Treatment Strategy
The approach to MAPCAs reflects a centre-specific philosophy:

• Hanley/Stanford approach (surgical unifocalization): Complete staged surgical unifocalization — joining all MAPCAs (sole- and dual-supply) into a neo-pulmonary arterial confluence before or simultaneous with complete repair — eliminates the need for extensive pre-operative catheter-based coiling. Dual-supply MAPCAs are ligated at surgery. This approach prioritises maximising total lung segment supply, avoiding MAPCA hypertensive pulmonary vascular disease.
• Hybrid/catheter-first approach: Dual-supply MAPCAs are coiled in the catheterisation laboratory before or after surgical unifocalization of sole-supply MAPCAs. This reduces the surgical complexity and volume of unifocalization required at the operating table, particularly at centres less experienced in complete unifocalization.
• Both strategies have been reported with good outcomes; centre expertise is the dominant determinant of results. Collaboration between interventional cardiologists and congenital cardiac surgeons at experienced multidisciplinary centres is essential.

• Reduction of volume overload: Eliminating dual-supply collaterals decreases pulmonary overcirculation, reducing right and left ventricular volume load, improving cardiac function, and simplifying post-operative haemodynamics after right ventricular outflow tract reconstruction.
• Prevention of hypertensive pulmonary vascular disease: Dual-supply MAPCAs transmit systemic aortic pressure to previously unprotected pulmonary segments, driving pulmonary hypertension and vascular remodelling. Early coiling prevents progression of this irreversible process, preserving operability of affected lung segments.
• Minimally invasive alternative to surgical ligation: Catheter-based MAPCA coiling avoids thoracotomy for ligation of dual-supply vessels, reducing morbidity and recovery time between staged palliation procedures.
• Optimises conditions for complete repair: Coiling of competitive dual-supply collaterals before or after complete repair (VSD closure + RVOT reconstruction) improves early post-operative haemodynamics and reduces re-intervention rates.
• Treatment of haemoptysis: In older patients with large, high-pressure MAPCAs causing haemoptysis, catheter embolisation achieves rapid bleeding control without major surgery.

• Inadvertent occlusion of sole-supply vessel: If a vessel classified as dual-supply actually provides unique perfusion to a pulmonary segment, coiling produces irreversible infarction of that segment. Meticulous pre-procedural mapping and balloon occlusion testing minimise but do not eliminate this risk.
• Spinal cord ischaemia (paraplegia): The most feared complication of thoracic MAPCA coiling. Occurs if the artery of Adamkiewicz or an anterior radiculomedullary artery shares origin with or is inadvertently embolised during MAPCA coiling. Risk is mitigated by meticulous pre-procedural spinal artery mapping, selective angiography of all target vessels, and balloon occlusion testing with neurological monitoring (MEP/SEP in patients under general anaesthesia).
• Recanalization: High-pressure aortic flow within MAPCAs promotes recanalization of the embolised segment through thrombus organisation and collateral recruitment. Rates depend on device choice (lower with AVP II vs coils alone) and MAPCA diameter. Recanalization requires repeat catheterisation and re-embolisation.
• Device embolisation: Inadvertent migration of a coil or AVP device into the central circulation (pulmonary artery, right ventricle, aorta); may require retrieval via catheter snare or surgical intervention.
• Stroke: Systemic thromboembolism from catheter manipulation in the aorta or intracardiac passage through a patent foramen ovale; managed with systemic heparinisation during the procedure.
• Access site complications: Femoral or radial artery haematoma, pseudoaneurysm, arteriovenous fistula — especially in small infants and young children with small vessel calibre.
• Radiation exposure: Prolonged fluoroscopy time in complex MAPCA mapping procedures; dose reduction protocols (pulsed fluoroscopy, collimation) are mandatory, especially in children.

Post-procedure surveillance for MAPCA coiling requires integration with the overall staged repair plan:

• Immediately post-procedure: Monitoring in the congenital cardiac ward for haemodynamic stability; oxygen saturation trends (sustained desaturation suggests inadvertent sole-supply coiling); neurological assessment (lower limb power and sensation) immediately on recovery to detect spinal cord ischaemia.
• Early follow-up (4–12 weeks): Echocardiography to assess ventricular function and estimate pulmonary artery pressures. Clinical assessment of exercise tolerance, oxygen requirements, and cardiac failure symptoms.
• Repeat catheterisation for recanalization assessment: Typically performed at 3–6 months post-coiling, or before the next planned surgical stage. Selective angiography of previously coiled MAPCAs to confirm persistent occlusion; residual or recanalised flow requires repeat embolisation.
• Cardiac MRI follow-up: Used to quantify total pulmonary blood flow (Qp:Qs), ventricular volumes, and pulmonary artery growth after unifocalization or coiling. Essential for planning VSD closure and assessing readiness for complete repair (pulmonary artery index, McGoon ratio).
• Long-term surveillance: After complete repair (VSD closure, RVOT reconstruction), annual cardiology review with echocardiography. Cardiac catheterisation with haemodynamic assessment every 3–5 years to monitor pulmonary artery pressures and RV function. Re-intervention rates are significant — conduit replacement for RVOT obstruction, balloon dilation of pulmonary artery stenoses, and re-coiling of recanalised MAPCAs are frequently required during follow-up.

MAPCA coiling is performed at specialist congenital heart disease centres and requires highly experienced interventional cardiologists:

• Diagnostic cardiac catheterisation with MAPCA mapping: USD 3,000–8,000 in India at AIIMS, PGIMER, or Narayana Health; USD 15,000–30,000 in the United States.
• MAPCA coiling procedure (catheter-based embolisation): USD 4,000–15,000 in India depending on number of vessels and devices used; USD 20,000–50,000 in the United States and Western Europe, inclusive of intensive care stay.
• Amplatzer Vascular Plug II device cost: USD 500–1,500 per device (varies by country and import duty); multiple devices may be required per session.
• Surgical unifocalization (Hanley procedure): USD 15,000–40,000 in India; USD 80,000–200,000 in the United States — covers multiple prior catheterisation staging procedures.
• Cardiac MRI for pre- and post-procedural mapping: USD 500–2,000 per scan in India; USD 5,000–10,000 in the US. Repeated MRI scans are required throughout the staged repair pathway.
• Overall staged repair (birth to complete repair) cost: Total treatment cost for TOF-PA with MAPCAs through complete staged repair is USD 30,000–80,000 in India and USD 300,000–500,000 or more in the United States, reflecting multiple hospitalisations, ICU stays, procedures, and long-term follow-up.

India (AIIMS New Delhi, Narayana Hrudayalaya Bangalore, PGIMER Chandigarh) is a major global destination for complex congenital heart surgery including MAPCA management, offering highly experienced congenital cardiac surgical teams at a fraction of Western costs. Many Indian centres treat MAPCAs under the Rashtriya Bal Swasthya Karyakram (RBSK) government programme for children below the poverty line.

• Complete surgical unifocalization (Hanley procedure): At Stanford Medical Center and other experienced centres, all MAPCAs (sole- and dual-supply) are surgically unifocalised into a central pulmonary arterial confluence in a single or staged operation, without prior catheter-based coiling of dual-supply vessels. Published results show excellent rates of complete repair (VSD closure) and superior pulmonary artery growth when all blood supply is centralised. This avoids the risks of catheter-based embolisation but requires the highest level of surgical expertise.
• Systemic-to-pulmonary shunt (Blalock-Taussig-Thomas shunt): A modified Blalock-Taussig-Thomas shunt (MBTS — subclavian-to-pulmonary artery anastomosis) may be used as initial palliation in infants with inadequate true pulmonary artery size, to promote central pulmonary artery growth before complete repair. This is an alternative or complement to early unifocalization.
• Balloon dilation of stenotic MAPCAs: Stenotic MAPCAs may be balloon-dilated at catheterisation to restore flow to sole-supply segments, improving pulmonary artery pressure gradients and making affected segments more amenable to surgical incorporation at unifocalization.
• Stenting of stenotic native pulmonary arteries or MAPCAs: Endovascular stents (bare-metal or covered) can scaffold stenotic segments of MAPCAs or hypoplastic true pulmonary arteries, serving as a bridge to complete surgical repair — particularly relevant in infants not yet ready for surgery.
• Cardiac transplantation: In patients with inoperable pulmonary vascular disease from long-standing unobstructed MAPCA supply, or failed prior unifocalization attempts with severely elevated pulmonary vascular resistance, heart-lung transplantation may be the only option — rarely available for this indication in most countries.